Abionyx Pharma (FRA:609) Float Percentage Of Total Shares Outstanding: 0.00% (As of Jul. 04, 2026)


FRA:609 Abionyx Pharma FRA:609
19 GF Score
Price €1.99
GF Value €0.82
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Abionyx Pharma Float Percentage Of Total Shares Outstanding?

Abionyx Pharma FRA:609 -3.16% 19 Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 04, 2026. GuruFocus rates FRA:609 with a GF Score™ of 19/100 and a GF Value™ of €0.82 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Abionyx Pharma's float shares is 0.00 Mil. Abionyx Pharma's total shares outstanding is 42.31 Mil. Abionyx Pharma's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Abionyx Pharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Abionyx Pharma's Institutional Ownership is 0.23%.

FRA:609
19GF Score
Abionyx Pharma FRA:609
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abionyx Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Abionyx Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/42.31
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 0.00% mean?
Abionyx Pharma (FRA:609) has a Float Percentage Of Total Shares Outstanding of 0.00% as of Jul. 04, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Abionyx Pharma and its competitors.
Is Abionyx Pharma's Float Percentage Of Total Shares Outstanding too high?
Abionyx Pharma's current Float Percentage Of Total Shares Outstanding is 0.00%. Overall, Abionyx Pharma has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
Abionyx Pharma's Float Percentage Of Total Shares Outstanding of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Abionyx Pharma and its competitors. Abionyx Pharma's current Float Percentage Of Total Shares Outstanding is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (FRA:609) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.82, compared to a current price of €1.99 — trading 142.7% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 0.00%. Abionyx Pharma's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Abionyx Pharma (FRA:609), the current Float Percentage Of Total Shares Outstanding is 0.00% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abionyx Pharma (FRA:609) Overvalued in 2026?

Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued. The current stock price of €1.99 is trading 142.7% above its estimated GF Value™ of €0.82. GuruFocus considers Abionyx Pharma to be Significantly Overvalued.

Key valuation signals for FRA:609:

  • Float Percentage Of Total Shares Outstanding: 0.00%
  • GF Value™: €0.82 vs. price of €1.99 (142.7% above fair value)
  • GF Score™: 19/100 with 4 warning signs

No single metric tells the full story. See the FRA:609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abionyx Pharma Business Description

Address 33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
19GF Score

Get the complete analysis for FRA:609

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.99
Price
€0.82
GF Value